Our expertise
Monoclonal antibodies (mAbs) have become a cornerstone of modern life science research and drug development. Their exquisite specificity allows them to bind to unique targets on proteins, cells, or pathogens. This specificity makes them invaluable tools for a wide range of applications.
Leveraging advanced technology, Eurofins CDMO adeptly manages diverse batch sizes. With 200 L fed-batch and perfusion capabilities, Eurofins CDMO is dedicated to the development and scaling of monoclonal antibodies (mAbs) and other mammalian-based therapeutic proteins.
Antibody-drug conjugates (ADCs) represent a breakthrough in targeted cancer therapy. They utilize the exquisite specificity of monoclonal antibodies to deliver potent cytotoxic payloads directly to cancer cells. This specificity offers the potential for significant therapeutic benefit with reduced systemic toxicity compared to traditional chemotherapy.
Eurofins CDMO offers a comprehensive suite of services to support your ADC programs, from early discovery to clinical trials.
Antibodies expertise
- Growth Media Optimization: To maximize product yield, Eurofins CDMO provides titer optimization for cell culture media
- Cell Banking: With extensive capabilities for development, manufacturing and characterization of cell banks, Eurofins CDMO offers cell banking services for research cell banks (RCBs)
- Cell Storage: Eurofins CDMO provides customized services according to client’s needs, and can efficiently store cell research cell banks (RCBs), Master Cell Banks (MCBs) and Working Cell Banks (WCBs)
- Process Development & Scale Up: Using Design of Experiments (DoE) approach, Eurofins CDMO integrates, single-use processing trains to develop processes that simplify manufacturing and reduce contamination risks. Our expertise is up to Risk Group 2 for exosomes, VLPs, EVLPs, ADCs, mAbs and recombinant proteins
- Upstream Processing: Eurofins CDMO provides comprehensive metabolite and cell physiology analysis and automated small scale development
- Downstream Processing: Flexible in protein purification sources, Eurofins CDMO uses mammalian cell culture for the production of therapeutic proteins and mAbs, as well as the use of other feedstocks, including transgenic plants, transgenic milks, and plasma.
Antibody Drug Conjugates
Eurofins CDMO is dedicated to delivering comprehensive manufacturing solutions for Antibody Drug Conjugates (ADCs). By integrating our biologics, small molecules (both linkers and warheads), and conjugation capabilities, we offer an all-encompassing solution, that includes:
- mAb Development and Manufacturing: Our Biologics division specializes in mAb production for both non-GMP and GMP purposes, catering to animal studies, toxicity assessments, and clinical trials. We excel in producing mAbs that serve as the drug substance and targeting moiety in ADCs.
- Linker-Payload Production: Leveraging our established expertise in small molecule manufacturing, we are proficient in synthesizing linkers and payloads, with capacity for Highly Potent Active Pharmaceutical Ingredients (HPAPIs), required for ADC formation. This capability ensures seamless integration of the linker-payload and ADC manufacturing processes.
To learn more